Mechanisms for Activation of Beige Adipose Tissue in Humans
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed
for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance
and adipose tissue in prediabetic patients